MOTS-c and exercise: the mitokine that mimics physical activity

A plain-English read on a small peptide that rises with exercise and signals metabolic flexibility.

TL;DR

• MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA.
• It rises in human blood after exercise and reproduced several exercise-related effects in mouse studies.
• FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.

What it is

MOTS-c (in plain English: mitochondrial open reading frame of the 12S rRNA-c, a 16-amino-acid peptide encoded by a small piece of mitochondrial DNA) is one of a handful of peptides known to come directly from the mitochondria themselves. The category name researchers use is mitokine (in plain English: a hormone-like signal released by mitochondria, the small power plants inside every cell). MOTS-c is the most-studied member of that family (Reynolds et al., Aging Cell, 2018).

How it works

Imagine your mitochondria as power plants that, when stressed by hard work, send a memo to the rest of the body: "We are pushing harder — please help us handle the fuel." MOTS-c is one of those memos. In published rodent research, MOTS-c administration improved how skeletal muscle handles glucose, reduced age-related insulin resistance, and increased physical performance — effects that overlap with what regular exercise produces (Lee et al., Cell Metab, 2015). Human studies have confirmed that MOTS-c levels in blood rise after exercise, particularly after high-intensity work (Reynolds et al., 2018; Yang et al., Sci Rep, 2018).

Who asks about it

People come to this topic after a longevity podcast labels MOTS-c "the exercise peptide" and they want to know if it can replace a workout. The honest answer is no peptide replaces training. The exercise-mimetic label captures a pattern in animal data — not a clinical promise.

What the research says

The original 2015 Cell Metabolism paper showed that MOTS-c administration improved metabolic markers in mice (Lee et al., 2015). A 2018 paper in Aging Cell documented that human MOTS-c levels declined with age and rose acutely after exercise (Reynolds et al., 2018). A 2018 paper in Scientific Reports extended that exercise-response finding (Yang et al., 2018). Human clinical trial data on exogenous MOTS-c administration remains limited compared with the animal literature.

What to know before considering it

FDA removed MOTS-c from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, MOTS-c is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. The published evidence base is mostly preclinical and observational. Future clinical use depends on FDA's decision and on the pace of human trials.

The Halftime POV

MOTS-c is the kind of molecule that turns longevity research into a useful conversation. The biology is novel. The exercise-rise pattern is suggestive. The human outcome data is thin. We will not pretend a peptide replaces a workout. We will keep reading.

Related reading:

• MOTS-c: the mitochondria-derived peptide explained
• MOTS-c: the mitochondria-derived peptide in the literature
• MOTS-c and longevity: why a mitochondrial peptide has researchers paying attention

---

FAQ

Q: What is MOTS-c? A: MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA. It was discovered in 2015 and is studied as a hormone-like signal influencing metabolic flexibility in animal and cell research.

Q: Is MOTS-c an exercise mimetic? A: MOTS-c rises in human blood after exercise in published research, and exogenous MOTS-c reproduced several exercise-related metabolic effects in mouse studies. Researchers describe it as exercise-mimetic — a label that captures the pattern, not a clinical claim.

Q: Is MOTS-c available in 2026? A: FDA removed MOTS-c from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, MOTS-c is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

---

Disclaimer

Several peptides discussed in this article — including MOTS-c — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Reynolds JC et al., Aging Cell, 2018 — MOTS-c is an exercise-induced mitochondrial-encoded peptide
• Yang Y et al., Scientific Reports, 2018 — Exercise-induced MOTS-c response in human skeletal muscle

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.